BASMA.com Raises a $3M Series A Round to Scale Up Its Health Tech Platform in the MENA

BASMA.com is a digital healthcare platform working on redefining the orthodontics support experience with a chain of digitally-equipped clinics to offer faster and more precise treatments through its licensed partners.

It uses ISO and CE certified invisible teeth aligners, 3D-printed in-house, to assist its network of partner clinics to treat patients with mild to moderate cases of teeth crowding and spacing in an average of 6 months. Unlike traditional orthodontic solutions, invisible aligners straighten teeth discreetly and without any pain.

Being the first of its kind in MENA, BASMA.com broke the barriers of traditional orthodontics by reshaping the patient experience. The startup has embraced a fully digital nature and took the process of orthodontic treatment to a new level. Pairing its network of partner clinics with state-of-the-art 3D technology, BASMA.com is on a mission to make customers’ experience more affordable and accessible.

Boosted by these new resources, BASMA.com will focus on hiring new talent and expanding its geographic reach across the Middle East. The startup also plans on growing its network of partner dental clinics across KSA, UAE, and the region, to reach more cities and countries in the GCC.

“With the social changes happening across MENA, we believe that the future of dental care is linking patients with doctors digitally. We have been following Dr. Cherif and his team for a while and are very excited about the progress made in serving clients across MENA using an end-to-end digital experience,” remarked Riyad Abou Jaoudeh, Junior Partner at MEVP.

“We believe in a full digital dental workflow and are equipping our network of clinics with all the digital tools necessary to offer accurate and effective treatments. At a click of a button, our users are directly connected to their dentists and orthodontists. Our advantage and main strength is that we make all of the treatment planning in-house, we listen and take the feedback of the patients, transmit it to our network partner clinics and constantly improve our offering,”  elaborates Dr. Cherif Massoud, CEO and co-founder of BASMA.com.

 

SourceBASMA.com

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”